Teva Pays $512 Million to Settle Claims of Delaying Generics

This week, Cephalon, a subsidiary of the drug maker Teva Pharmaceutical Industries, said that it had agreed to pay $512 million to settle claims that Cephalon paid generic manufacturers to keep their own cheaper versions of a drug used to treat narcolepsy off the market. This Supreme Court ruled in 2013 that such practices, typically called reverse payment settlements, may be illegal. [4/21/15]

Search